Tirzepatide Supply Update: Costs & Alternatives

Why Did Compounding Pharmacies Stop Producing Tirzepatide?

The U.S. Food and Drug Administration (FDA) permits compounding pharmacies to produce medications only during shortages. With the tirzepatide shortage designated as “resolved”, these pharmacies are no longer authorized to compound it. While this signals an improvement in the availability of Mounjaro® and Zepbound®, it has left many patients seeking more affordable alternatives.

In compliance with FDA regulations, compounded tirzepatide is no longer available from any provider, including Alan Meds.

What Does This Mean for Patients?

For many individuals managing type 2 diabetes and obesity, tirzepatide (the active ingredient in Mounjaro® and Zepbound®) has played a key role in their treatment plans. With the recent FDA announcement confirming the resolution of the tirzepatide shortage, patients who once turned to compounded tirzepatide as an affordable option are now faced with new hurdles—primarily the steep cost of brand-name medications.

The Financial Impact of Shortage Resolution

While the shortage resolution has improved access to brand-name drugs like Mounjaro® and Zepbound®, it also highlights their steep price tags. For those without sufficient insurance coverage, these FDA-approved medications can cost over $1,000 per month, creating a serious financial strain.

During the shortage, compounded tirzepatide provided a more accessible alternative. State-licensed compounding pharmacies helped fill the supply gap, enabling affordable care for millions of patients. Now that compounded tirzepatide is no longer available, patients are left with higher-cost brand-name drugs or the option to switch to other treatments, such as compounded semaglutide.

Balancing Affordability and Care

The transition from compounded tirzepatide to more expensive brand-name medications is placing a financial burden on many patients, especially those without comprehensive insurance. Increased out-of-pocket costs may force some to reduce or stop treatment, potentially impacting their progress in managing diabetes or weight loss.

For patients who relied on compounded tirzepatide, this transition threatens to disrupt the continuity of their care. However, Alan Meds is here to support you. We offer compounded semaglutide, an effective and affordable alternative, to ensure that your health journey continues without unnecessary financial pressure.

Compounded Semaglutide as an Alternative

With compounded tirzepatide no longer available, compounded semaglutide is an excellent alternative for managing both type 2 diabetes and weight loss. Like tirzepatide, semaglutide is a GLP-1 receptor agonist that helps regulate appetite and blood sugar levels, offering effective results without the high cost.  Studies show that semaglutide can reduce body fat by up to 15%. (source)

At Alan Meds, compounded semaglutide is available for just $297 for the first month and $397 per month thereafter—offering a much more affordable option compared to brand-name tirzepatide medications like Mounjaro® and Zepbound®, which can exceed $1,000 per month without insurance.

We are committed to helping our patients maintain their health journeys without financial burden. Our healthcare team is ready to guide you through this transition and provide the medications, care, and support you need to continue achieving your health goals confidently and affordably.

How Can I Switch to Compounded Semaglutide to Stay on Track?

At Alan Meds, we’re here to support you. Your doctor will be able to discuss the best plan for your specific health needs and guide you through the transition to semaglutide without you losing the progress you've made on your tirzepatide program. Our care team will work with you to ensure that you have access to the medications and support you need for your treatment journey.

Conclusion: Balancing Costs While Ensuring Access to Care

Although the resolution of the tirzepatide shortage is positive from a supply perspective, it introduces a new financial challenge for many patients.

At Alan Meds, we’re committed to offering affordable and effective options like compounded semaglutide. If you’re concerned about your prescription or medication costs, our team is here to help you find the best solutions for your healthcare needs.

See if you qualify for compounded semaglutide here.

---

Frequently Asked Questions

What does the end of compounded tirzepatide availability mean for me?

With the shortage resolved, compounded tirzepatide is no longer available to new customers. You can switch to compounded semaglutide or explore brand-name options like Mounjaro® and Zepbound®.

What are my options with Alan Meds for continuing treatment?

Orders placed before October 2, 2024 will be fulfilled. For auto-refills or to switch treatments, consult your doctor through the patient portal or reach out to  help@alanmeds.com. Compounded semaglutide GLP-1 medicaiton is available at $397 per month thereafter.

I have an existing tirzepatide prescription that was written by the doctor but I haven’t received it yet. Will my order be shipped?

New customer orders accepted by the pharmacy before 11:59 p.m. on October 2, 2024, will be shipped. New customer orders placed after this deadline will be canceled automatically.

If you have further questions, our team is ready to support you in navigating your options and finding the right treatment path. Please reach out to help@alanmeds.com – we’re here to help!